The FDA said it will increase resources for overseas bioresearch monitoring inspections and update risk-based criteria used to select foreign clinical trial sites for audit. The agency tied the move to concerns about regulatory capacity abroad and the practical challenges of performing the same level of oversight—including unannounced inspections—as it does domestically. In a blog post, acting director Michael Davis (Center for Drug Evaluation and Research) said the FDA expects growing scrutiny in Phase I and early-stage trials, while it plans to strengthen training for medical product reviewers to identify sites where Good Clinical Practice compliance may be uncertain. The FDA also flagged concerns about how easily results from multiregional trials without American patients can generalize to U.S. populations. The shift lands as the FDA faces persistent questions from lawmakers and industry about inspection coverage, reliability, and whether foreign trial findings can be trusted consistently across regions. By recalibrating inspection targeting and building reviewer capabilities, the agency appears to be attempting to close gaps in oversight while managing limited inspection capacity. For sponsors, the announcement increases the likelihood of expanded documentation and audit readiness for clinical programs conducted overseas, especially those early in development where FDA can still shape the eventual data package for U.S. review.